- Walgreens partners with United Nations Foundation's Shot@Life campaign
- Study: Cough-cold manufacturers' voluntary label change on pediatric products reduced ER admissions
- Walgreens partners with Chicago Public Schools and city health department on Tdap vaccination project
- Cardinal Health invites independent pharmacy owners to ‘discover new horizons’ at RBC 2013
- PhRMA report lists 271 vaccines in development
DEERFIELD, Ill. — Takeda Pharmaceutical has launched a new treatment for high blood pressure, the company said Friday.
Takeda announced the launch of Edarbi (azilsartan medoxomil), which the Food and Drug Administration approved on Feb. 25 as a once-daily pill for hypertension.
“Hypertension is a serious condition but typically does not have any symptoms, and many aren’t aware of the long-term impact hypertension has on cardiovascular health,” Takeda Pharmaceuticals North America executive medical director of medical and scientific affairs Paulos Berhanu said. “We are pleased to make available Edarbi, an important new treatment option for patients with hypertension and the healthcare professionals who treat them.”